Viewing Study NCT00381550

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:25 PM
Ignite Modification Date: 2026-01-24 @ 3:28 AM
Study NCT ID: NCT00381550
Status: COMPLETED
Last Update Posted: 2015-01-06
First Post: 2006-09-26
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Accelerated Phase Chronic Myelogenous Leukemia View
None Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative View
None Blastic Phase Chronic Myelogenous Leukemia View
None Chronic Eosinophilic Leukemia View
None Chronic Myelomonocytic Leukemia View
None Essential Thrombocythemia View
None Philadelphia Chromosome Negative Chronic Myelogenous Leukemia View
None Polycythemia Vera View
None Primary Myelofibrosis View
None Relapsing Chronic Myelogenous Leukemia View
Keywords: